This article is more than 5 years old. Information may no longer be current.
Johnson & Johnson Vision completes TearScience acquisition
Click Here to Manage Email Alerts
Johnson & Johnson Vision’s acquisition of TearScience has been completed, according to a company press release.
The company announced in August that it would acquire TearScience, which has FDA clearance for products to evaluate meibomian gland health and treat meibomian gland dysfunction, the leading cause of dry eye disease. Financial terms of the deal were not disclosed.
“Dry eye is too often the culprit of why patients drop out of contact lenses or why they may have a less than optimal outcome from their cataract surgery,” Ashley McEvoy, Johnson & Johnson Vision company group chairman, said in the release. “The medical device technologies from TearScience will allow us to address the main underlying cause of dry eye, giving us a mechanical solution to a mechanical problem.”